

# Frederic Lagarce

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1205558/publications.pdf>

Version: 2024-02-01

58  
papers

2,598  
citations

186265

28  
h-index

182427

51  
g-index

62  
all docs

62  
docs citations

62  
times ranked

4068  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. <i>Nanomedicine</i> , 2010, 5, 287-306.	3.3	264
2	Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules. <i>Pharmaceutical Research</i> , 2006, 23, 1243-1250.	3.5	258
3	Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. <i>Journal of Controlled Release</i> , 2009, 140, 174-181.	9.9	237
4	Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. <i>Drug Discovery Today</i> , 2015, 20, 899-905.	6.4	199
5	Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection. <i>Journal of Controlled Release</i> , 2017, 264, 45-54.	9.9	107
6	Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 79, 181-188.	4.3	97
7	Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. <i>Journal of Controlled Release</i> , 2016, 225, 283-293.	9.9	96
8	Lipid nanocapsules: Ready-to-use nanovectors for the aerosol delivery of paclitaxel. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 73, 239-246.	4.3	86
9	Models for drug absorption from the small intestine: where are we and where are we going?. <i>Drug Discovery Today</i> , 2017, 22, 761-775.	6.4	85
10	The gastrointestinal stability of lipid nanocapsules. <i>International Journal of Pharmaceutics</i> , 2009, 379, 260-265.	5.2	82
11	Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation. <i>International Journal of Pharmaceutics</i> , 2015, 481, 154-161.	5.2	82
12	How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 320-336.	13.7	78
13	Mucus models to evaluate nanomedicines for diffusion. <i>Drug Discovery Today</i> , 2014, 19, 1097-1108.	6.4	68
14	Toxicological Study and Efficacy of Blank and Paclitaxel-Loaded Lipid Nanocapsules After i.v. Administration in Mice. <i>Pharmaceutical Research</i> , 2010, 27, 421-430.	3.5	61
15	Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 40, 422-429.	4.0	52
16	Development of 2D and 3D Mucus Models and Their Interactions with Mucus-Penetrating Paclitaxel-Loaded Lipid Nanocapsules. <i>Pharmaceutical Research</i> , 2014, 31, 1753-1765.	3.5	45
17	Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: In vitro and in vivo evaluation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2005, 61, 171-180.	4.3	41
18	Gemcitabine and glioblastoma: challenges and current perspectives. <i>Drug Discovery Today</i> , 2018, 23, 416-423.	6.4	40

#	ARTICLE	IF	CITATIONS
19	Advances in treatment formulations for acute myeloid leukemia. Drug Discovery Today, 2018, 23, 1936-1949.	6.4	40
20	Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide. European Journal of Pharmaceutical Sciences, 2013, 50, 172-180.	4.0	39
21	<i>In vivo</i> evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor. Nanomedicine, 2015, 10, 589-601.	3.3	39
22	Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. International Journal of Nanomedicine, 2013, 8, 4291.	6.7	38
23	Cytotoxicity and genotoxicity of lipid nanocapsules. Toxicology in Vitro, 2017, 41, 189-199.	2.4	36
24	Comparison of Raman spectroscopy vs. high performance liquid chromatography for quality control of complex therapeutic objects: Model of elastomeric portable pumps filled with a fluorouracil solution. Journal of Pharmaceutical and Biomedical Analysis, 2014, 91, 176-184.	2.8	34
25	Evaluation of lauroyl-gemcitabine-loaded hydrogel efficacy in glioblastoma rat models. Nanomedicine, 2018, 13, 1999-2013.	3.3	34
26	Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 449-459.	4.3	31
27	Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. International Journal of Nanomedicine, 2011, 6, 2941.	6.7	30
28	Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide. Drug Discovery Today, 2015, 20, 772-779.	6.4	28
29	Development and characterization of interleukin-18-loaded biodegradable microspheres. International Journal of Pharmaceutics, 2006, 314, 179-188.	5.2	25
30	Oxaliplatin loaded PLGA microspheres. International Journal of Pharmaceutics, 2002, 242, 243-246.	5.2	24
31	The adaptation of lipid nanocapsule formulations for blood administration in animals. International Journal of Pharmaceutics, 2009, 379, 266-269.	5.2	24
32	Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide. International Journal of Nanomedicine, 2014, 9, 1479.	6.7	22
33	Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia. International Journal of Nanomedicine, 2017, Volume 12, 8427-8442.	6.7	16
34	Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas. International Journal of Pharmaceutics, 2016, 509, 279-284.	5.2	15
35	Nucleic-Acid Delivery Using Lipid Nanocapsules. Current Pharmaceutical Biotechnology, 2016, 17, 723-727.	1.6	15
36	Successful treatment of a recurrent AspergillusÂniger otomycosis with local application of voriconazole. Journal De Mycologie Medicale, 2018, 28, 396-398.	1.5	13

#	ARTICLE	IF	CITATIONS
37	GERPAC Consensus Conference "Guidance on the Assignment of Microbiological Shelf-life for Hospital Pharmacy Aseptic Preparations. Pharmaceutical Technology in Hospital Pharmacy, 2020, 5, .	0.4	13
38	Development of new polymer-based particulate systems for anti-glioma vaccination. International Journal of Pharmaceutics, 2006, 309, 1-5.	5.2	12
39	Design and stability study of a paediatric oral solution of methotrexate 2mg/ml. International Journal of Pharmaceutics, 2015, 487, 270-273.	5.2	12
40	Stability of micafungin sodium solutions at different concentrations in glass bottles and syringes. International Journal of Pharmaceutics, 2015, 492, 137-140.	5.2	8
41	Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats. International Journal of Nanomedicine, 2017, Volume 12, 8159-8170.	6.7	7
42	Biopharmaceutics of intrathecal baclofen-loaded microparticles in a goat model. International Journal of Pharmaceutics, 2005, 298, 68-79.	5.2	6
43	&lt;p&gt;Di&lt;em&gt;O&lt;/em&gt;-lauroyl-decibaine-lipid nanocapsules: toward extending decitabine activity&lt;/p&gt;. International Journal of Nanomedicine, 2019, Volume 14, 2091-2102.	6.7	6
44	Is the translational approach becoming a reality in nanomedicine?. European Journal of Nanomedicine, 2015, 7, .	0.6	3
45	Nanomedicines: are we lost in translation?. European Journal of Nanomedicine, 2015, 7, .	0.6	3
46	Stability of a 50&lt;sup&gt;mg&lt;/sup&gt;/mL Ceftazidime Eye-Drops Formulation. Pharmaceutical Technology in Hospital Pharmacy, 2018, 3, 219-226.	0.4	3
47	Specificity of pharmacokinetic modeling of nanomedicines. Drug Discovery Today, 2021, 26, 2259-2268.	6.4	3
48	Combined silencing expression of MGMT with EGFR or galectin-1 enhances the sensitivity of glioblastoma to temozolomide. European Journal of Nanomedicine, 2015, 7, .	0.6	2
49	Centrally Prepared Cytotoxic Drugs: What Is the Purpose of Their Quality Control?. Pharmaceutical Technology in Hospital Pharmacy, 2017, 2, .	0.4	2
50	Quality in Stability Testing. Pharmaceutical Technology in Hospital Pharmacy, 2018, 3, 1-2.	0.4	1
51	Serving and studying during COVID&lt;sup&gt;19&lt;/sup&gt; pandemic. Clinical Teacher, 2021, 18, 224-225.	0.8	1
52	1208 Toxicity of systemic administration of blank and paclitaxel-loaded lipid nanocapsules in mice. European Journal of Cancer, Supplement, 2009, 7, 123.	2.2	0
53	Quality and Safety in the Hospital: The Pharmacist is the Key Person. Pharmaceutical Technology in Hospital Pharmacy, 2016, 1, .	0.4	0
54	Quality Assurance in Hospital Pharmacy Compounding Units is a Multi Player Game. Pharmaceutical Technology in Hospital Pharmacy, 2017, 2, .	0.4	0

#	ARTICLE	IF	CITATIONS
55	After Ten Issues Our Journal Has Found Its Audience and Main Topics. <i>Pharmaceutical Technology in Hospital Pharmacy</i> , 2018, 3, 121-122.	0.4	0
56	Methods for the Study of Physical and Chemical Stability and Container-Content Interactions: Report of a GERPAC Workshop. <i>Pharmaceutical Technology in Hospital Pharmacy</i> , 2019, 4, 95-97.	0.4	0
57	Nanomedicines: promises and reality. <i>Drug Discovery Today</i> , 2020, 25, 473-474.	6.4	0
58	New liquid oral formulations of hydroxychloroquine: a physicochemical stability study. <i>Pharmaceutical Technology in Hospital Pharmacy</i> , 2021, 6, .	0.4	0